Compare · HUM vs SERA
HUM vs SERA
Side-by-side comparison of Humana Inc. (HUM) and Sera Prognostics Inc. (SERA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUM and SERA operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $46.80B, about 544.1x SERA ($86.0M).
- Over the past year, HUM is up 30.1% and SERA is down 30.5% - HUM leads by 60.6 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- HUM has more recent analyst coverage (25 ratings vs 8 for SERA).
- Company
- Humana Inc.
- Sera Prognostics Inc.
- Price
- $388.85+0.65%
- $2.12+0.00%
- Market cap
- $46.80B
- $86.0M
- 1M return
- +2.03%
- +0.95%
- 1Y return
- +30.12%
- -30.49%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 6
- Recent ratings
- 25
- 8
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Sera Prognostics Inc.
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest HUM
- Humana Names Dr. Shantanu Nundy as Chief Medical Officer
- James P. Holland to Join Humana as Medicaid President
- Humana upgraded by Morgan Stanley with a new price target
- Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin
- Director Smith Paul John was granted 544 units of Humana Common (SEC Form 4)
- Director Crawford Frederick John was granted 544 units of Humana Common (SEC Form 4)
- Humana upgraded by Evercore ISI with a new price target
- Humana upgraded by Leerink Partners with a new price target
- Humana downgraded by Raymond James
- New insider Crawford Frederick John claimed ownership of 21 units of Humana Common (SEC Form 3)
Latest SERA
- 1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.
- Sera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
- SEC Form 10-Q filed by Sera Prognostics Inc.
- Sera Prognostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
- SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026
- Director Phillips Joshua was granted 24,686 shares, increasing direct ownership by 43% to 81,691 units (SEC Form 4)
- Director Mirza Mansoor Raza was granted 24,197 shares, increasing direct ownership by 42% to 81,937 units (SEC Form 4)
- Director Lawrence Sandra Aj was granted 24,702 shares, increasing direct ownership by 150% to 41,175 units (SEC Form 4)